메뉴 건너뛰기




Volumn 5, Issue 4, 2003, Pages

Conference report - Breast cancer markers: What next?

(1)  Mariani, Sara M a  

a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

EID: 25144491052     PISSN: None     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper
Times cited : (1)

References (34)
  • 1
    • 0030855116 scopus 로고    scopus 로고
    • Pathologic prognostic factors for patients with breast carcinoma. Which factors are important?
    • Weidner N, Cady B, Goodson WH 3rd. Pathologic prognostic factors for patients with breast carcinoma. Which factors are important? Surg Oncol Clin North Am. 1997;6:415-462.
    • (1997) Surg. Oncol. Clin. North Am. , vol.6 , pp. 415-462
    • Weidner, N.1    Cady, B.2    Goodson III, W.H.3
  • 2
    • 0028955244 scopus 로고
    • Prognostic factors in breast carcinoma
    • Weidner N. Prognostic factors in breast carcinoma. Curr Opin Obstet Gynecol. 1995;7:4-9.
    • (1995) Curr. Opin. Obstet. Gynecol. , vol.7 , pp. 4-9
    • Weidner, N.1
  • 3
    • 0041346051 scopus 로고    scopus 로고
    • Exploiting the hallmarks of cancer: The future conquest of breast cancer
    • Sledge GW Jr, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003;39:1668-1675.
    • (2003) Eur. J. Cancer , vol.39 , pp. 1668-1675
    • Sledge Jr., G.W.1    Miller, K.D.2
  • 4
    • 0028227085 scopus 로고
    • Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma
    • Gasparini G, Weidner N, Bevilacqua P, et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994;12:454-466.
    • (1994) J. Clin. Oncol. , vol.12 , pp. 454-466
    • Gasparini, G.1    Weidner, N.2    Bevilacqua, P.3
  • 5
    • 0028269324 scopus 로고
    • A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma
    • Gasparini G, Boracchi P, Bevilacqua P, et al. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat. 1994;29:59-71.
    • (1994) Breast Cancer Res. Treat. , vol.29 , pp. 59-71
    • Gasparini, G.1    Boracchi, P.2    Bevilacqua, P.3
  • 6
    • 0027494093 scopus 로고
    • Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade
    • Weidner N, Moore DH 2nd, et al. Correlation of bromodeoxyuridine (BRDU) labeling of breast carcinoma cells with mitotic figure content and tumor grade. Am J Surg Pathol. 1993;17:987-994.
    • (1993) Am. J. Surg. Pathol. , vol.17 , pp. 987-994
    • Weidner, N.1    Moore II, D.H.2
  • 7
    • 0028359509 scopus 로고
    • Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody
    • Weidner N, Moore DH 2nd, Vartanian R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum Pathol. 1994;25:337-342.
    • (1994) Hum. Pathol. , vol.25 , pp. 337-342
    • Weidner, N.1    Moore II, D.H.2    Vartanian, R.3
  • 8
    • 0036080841 scopus 로고    scopus 로고
    • New paradigm for vessel intravasation by tumor cells
    • Weidner N. New paradigm for vessel intravasation by tumor cells. Am J Pathol. 2002;160:1937-1939.
    • (2002) Am. J. Pathol. , vol.160 , pp. 1937-1939
    • Weidner, N.1
  • 9
    • 0037370476 scopus 로고    scopus 로고
    • The genetics and genomics of cancer
    • Balmain A, Gray J, Ponder B. The genetics and genomics of cancer. Nat Genet. 2003;33(suppl):238-244.
    • (2003) Nat. Genet. , vol.33 , Issue.SUPPL. , pp. 238-244
    • Balmain, A.1    Gray, J.2    Ponder, B.3
  • 10
    • 0035489608 scopus 로고    scopus 로고
    • Proteomics of breast cancer for marker discovery and signal pathway profiling
    • Hondermarck H, Vercoutter-Edouart AS, Revillion F, et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics. 2001;1:1216-1232.
    • (2001) Proteomics , vol.1 , pp. 1216-1232
    • Hondermarck, H.1    Vercoutter-Edouart, A.S.2    Revillion, F.3
  • 11
    • 25144449912 scopus 로고    scopus 로고
    • Breast cancer markers
    • Program and abstracts of the Annual Meeting of the American Society of Clinical Pathology; September 18-21, New Orleans, Louisiana
    • Weidner N. Breast cancer markers. Program and abstracts of the Annual Meeting of the American Society of Clinical Pathology; September 18-21, 2003; New Orleans, Louisiana.
    • (2003)
    • Weidner, N.1
  • 13
    • 0027979311 scopus 로고
    • Elevated ErbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer
    • Isola JJ, Holli K, Oksa H, et al. Elevated ErbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer. 1994;73:652-658.
    • (1994) Cancer , vol.73 , pp. 652-658
    • Isola, J.J.1    Holli, K.2    Oksa, H.3
  • 14
    • 0031034106 scopus 로고    scopus 로고
    • HER-2/neu signal transduction in human breast and ovarian cancer
    • Reese DM, Slamon DJ. HER-2/neu signal transduction in human breast and ovarian cancer. Stem Cells. 1997;15:1-8.
    • (1997) Stem. Cells , vol.15 , pp. 1-8
    • Reese, D.M.1    Slamon, D.J.2
  • 15
    • 0042208398 scopus 로고    scopus 로고
    • The Her-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy
    • Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.
    • (2003) Oncologist , vol.8 , pp. 307-325
    • Ross, J.S.1    Fletcher, J.A.2    Linette, G.P.3
  • 16
    • 0034666345 scopus 로고    scopus 로고
    • Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): A study of incidence and correlation with outcome in breast cancer
    • Thor AD, Liu S, Edgerton S, et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol. 2000;18:3230-3239.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 3230-3239
    • Thor, A.D.1    Liu, S.2    Edgerton, S.3
  • 17
    • 0032445260 scopus 로고    scopus 로고
    • HER-2/neu as a predictive marker of response to breast cancer therapy
    • Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat. 1998;52:65-77.
    • (1998) Breast Cancer Res. Treat. , vol.52 , pp. 65-77
    • Pegram, M.D.1    Pauletti, G.2    Slamon, D.J.3
  • 18
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2
    • Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N Engl J Med. 2001;344:783-792.
    • (2001) N. Engl. J. Med. , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 19
    • 0035873815 scopus 로고    scopus 로고
    • Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
    • Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001;19:2587-2595.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 2587-2595
    • Seidman, A.D.1    Fornier, M.N.2    Esteva, F.J.3
  • 20
    • 0035868668 scopus 로고    scopus 로고
    • 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology
    • for the American Society of Clinical Oncology Tumor Markers Expert Panel
    • Bast RC Jr, Ravdin P, Hayes DF, et al, for the American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19:1865-1878.
    • (2001) J. Clin. Oncol. , vol.19 , pp. 1865-1878
    • Bast Jr., R.C.1    Ravdin, P.2    Hayes, D.F.3
  • 21
    • 0028232729 scopus 로고
    • Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression
    • Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
    • (1994) Cancer Res. , vol.54 , pp. 2771-2777
    • Press, M.F.1    Hung, G.2    Godolphin, W.3    Slamon, D.J.4
  • 22
    • 0037099732 scopus 로고    scopus 로고
    • Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens
    • Press MF, Slamon DJ, Flom KJ, et al. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol. 2002;20:3095-3105.
    • (2002) J. Clin. Oncol. , vol.20 , pp. 3095-3105
    • Press, M.F.1    Slamon, D.J.2    Flom, K.J.3
  • 23
    • 0035189256 scopus 로고    scopus 로고
    • Current status of HER2 testing: Caught between a rock and a hard place
    • Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol. 2001;116:806-810.
    • (2001) Am. J. Clin. Pathol. , vol.116 , pp. 806-810
    • Schnitt, S.J.1    Jacobs, T.W.2
  • 24
    • 0037707280 scopus 로고    scopus 로고
    • HER2/neu expression in cancer: The pathologist as diagnostician or prophet?
    • Foster CS, Gosden CM, Ke Y. HER2/neu expression in cancer: the pathologist as diagnostician or prophet? Hum Pathol. 2003;34:635-638.
    • (2003) Hum. Pathol. , vol.34 , pp. 635-638
    • Foster, C.S.1    Gosden, C.M.2    Ke, Y.3
  • 25
    • 0344453811 scopus 로고    scopus 로고
    • The clinical evaluation of HER-2 status: Which test to use?
    • Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003;199:411-417.
    • (2003) J. Pathol. , vol.199 , pp. 411-417
    • Bartlett, J.1    Mallon, E.2    Cooke, T.3
  • 26
    • 0029884715 scopus 로고    scopus 로고
    • Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization
    • Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
    • (1996) Oncogene , vol.13 , pp. 63-72
    • Pauletti, G.1    Godolphin, W.2    Press, M.F.3    Slamon, D.J.4
  • 27
    • 0034327895 scopus 로고    scopus 로고
    • Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
    • Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
    • (2000) J. Clin. Oncol. , vol.18 , pp. 3651-3664
    • Pauletti, G.1    Dandekar, S.2    Rong, H.3
  • 28
    • 0037325177 scopus 로고    scopus 로고
    • Current perspectives on HER2 testing: A review of national testing guidelines
    • Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol. 2003;16:173-182.
    • (2003) Mod. Pathol. , vol.16 , pp. 173-182
    • Bilous, M.1    Dowsett, M.2    Hanna, W.3
  • 29
    • 0033694650 scopus 로고    scopus 로고
    • Chromogenic in situ hybridization: A practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples
    • Tanner M, Gancberg D, Di Leo A, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000;157:1467-1472.
    • (2000) Am. J. Pathol. , vol.157 , pp. 1467-1472
    • Tanner, M.1    Gancberg, D.2    Di Leo, A.3
  • 30
    • 0036677314 scopus 로고    scopus 로고
    • Chromogenic in situ hybridization: A novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma
    • Dandachi N, Dietze O, Hauser-Kronberger C. Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 2002;82:1007-1014.
    • (2002) Lab. Invest. , vol.82 , pp. 1007-1014
    • Dandachi, N.1    Dietze, O.2    Hauser-Kronberger, C.3
  • 31
    • 0038792812 scopus 로고    scopus 로고
    • Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer
    • Arnould L, Denoux Y, MacGrogan G, et al. Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer. Br J Cancer. 2003;88:1587-1591.
    • (2003) Br. J. Cancer , vol.88 , pp. 1587-1591
    • Arnould, L.1    Denoux, Y.2    MacGrogan, G.3
  • 32
    • 0037362714 scopus 로고    scopus 로고
    • Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer
    • Gupta D, Middleton LP, Whitaker MJ, Abrams J. Comparison of fluorescence and chromogenic in situ hybridization for detection of HER-2/neu oncogene in breast cancer. Am J Clin Pathol. 2003;119:381-387.
    • (2003) Am. J. Clin. Pathol. , vol.119 , pp. 381-387
    • Gupta, D.1    Middleton, L.P.2    Whitaker, M.J.3    Abrams, J.4
  • 33
    • 0037333625 scopus 로고    scopus 로고
    • Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy
    • Park K, Kim J, Lim S, Han S. Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur J Cancer. 2003;39:631-634.
    • (2003) Eur. J. Cancer , vol.39 , pp. 631-634
    • Park, K.1    Kim, J.2    Lim, S.3    Han, S.4
  • 34
    • 0037341394 scopus 로고    scopus 로고
    • Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: A nationwide population-based study
    • Joensuu H, Isola J, Lundin M, et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res. 2003;9:923-930.
    • (2003) Clin. Cancer Res. , vol.9 , pp. 923-930
    • Joensuu, H.1    Isola, J.2    Lundin, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.